CONGLETON JON (Chief Executive Officer) sold 9.6% of their position (75K shares) of MINERALYS THERAPEUTICS, INC. on the open market
Open‑market sale worth $1.97M — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 4/2/2026ACC: 0001644975-26-000004
DirectorOfficer· Chief Executive Officer
Since Feb 2026
-75K
Net shares
Net seller
$1.97M
Total sold
3
Open market trades
0B · 3S
3
Total transactions
75K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
−19.36K
Price / share
$25.50
Trade value
$493.79K
% of position
2.5%
3/31/2026
780.05K→760.69K
Common Stock
Direct
Shares
−55.18K
Price / share
$26.54
Trade value
$1.46M
% of position
7.3%
3/31/2026
760.69K→705.50K
Common Stock
Direct
Shares
−453.00
Price / share
$27.05
Trade value
$12.25K
% of position
0.1%
3/31/2026
705.50K→705.05K
Total
Net shares
−75K
Net value
-$1.97M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/31/2026 | S · Sale | −19.36K | $25.50 | $493.79K | 2.5% | 780.05K | 760.69K |
| Common Stock Direct | 3/31/2026 | S · Sale | −55.18K | $26.54 | $1.46M | 7.3% | 760.69K | 705.50K |
| Common Stock Direct | 3/31/2026 | S · Sale | −453.00 | $27.05 | $12.25K | 0.1% | 705.50K | 705.05K |
| Total | −75K | -$1.97M | ||||||
Derivative Transactions0
No derivative transactions reported